<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40088">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775423</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-101</org_study_id>
    <nct_id>NCT01775423</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Biomedical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Biomedical, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm, dose escalation study of BBI608 in patients with advanced
      malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Adverse events will be assessed at baseline, while the participant is taking BBI608, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of safety of BBI608 given in monotherapy to patients with advanced malignancies by reporting of adverse events and serious adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cancer, Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>BBI608</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <arm_group_label>BBI608</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Signed written informed consent must be obtained and documented according to
             International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the
             local regulatory requirements, and permission to use private health information in
             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior
             to study-specific screening procedures

          2. For solid tumors or lymphoma, a histologically or cytologically confirmed solid tumor
             that is metastatic, unresectable, or recurrent and for which standard curative or
             palliative therapies do not exist or are no longer effective.

          3. ≥ 18 years of age

          4. For solid tumors, measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST 1.1)

          5. For lymphoma, measurable disease as defined by the International Workshop to
             Standardize Response Criteria for Non-Hodgkin's Lymphoma

          6. For multiple myeloma, measurable disease as defined by the International Uniform
             Response Criteria for Multiple Myeloma

          7. Karnofsky performance status greater than or equal to 70%

          8. Male or female patients of child-producing potential must agree to use contraception
             or avoidance of pregnancy measures during the study and for 30 days after the last
             BBI608 dose

          9. Females of childbearing potential must have a negative serum pregnancy test

         10. Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 1.5
             × upper limit of normal(ULN)

         11. Hemoglobin (Hgb) greater than or equal to 10 g/dl

         12. Total bilirubin less than or equal to 1.5 × ULN

         13. Creatinine less than or equal to 1.5 x ULN or creatinine clearance greater than 60
             mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
             Creatinine &lt; 2.5 x ULN for multiple myeloma patients.

         14. Absolute neutrophil count greater than or equal to  1.5 x 109/L

         15. Platelets greater than or equal to 100 x 109/L

         16. Life expectancy greater than or equal to 3 months

        Exclusion Criteria

          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
             within four weeks of first dose with the exception for a single dose radiation up to
             8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days
             before beginning the administration of BBI608.

          2. Surgery within 4 weeks prior to first dose

          3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks
             after completion of that treatment, with image documentation required. Patients must
             have no clinical symptoms from brain metastases and must be either off steroids or on
             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients
             with known leptomeningeal metastases are excluded, even if treated.

          4. Pregnant or breastfeeding

          5. Significant gastrointestinal disorder(s), in the opinion of the Principal
             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small
             intestine resection)

          6. Unable or unwilling to swallow BBI608 capsules daily

          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, clinically significant non-healing or healing wounds, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant
             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Translational Oncology Research, Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kueber, RN</last_name>
      <phone>864-455-3600</phone>
      <email>jkueber@ghs.org</email>
    </contact>
    <investigator>
      <last_name>William J. Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Jonker, MD</last_name>
      <phone>613-737-7700</phone>
    </contact>
    <investigator>
      <last_name>Derek Jonker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirin Kazemi, PhD</last_name>
      <phone>(514)340-8222</phone>
      <phone_ext>4301</phone_ext>
      <email>skazemi@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Adrian Langleben, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
